2023 World Conference on Lung Cancer (Posters)-P2.05. Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1

P2.05. Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1 - PDF(Slides)

Back to course

Pdf Summary

The study analyzed the role of T-cell infiltration in patients with advanced non-small cell lung cancer (NSCLC) who received canakinumab as part of their treatment. High T-cell infiltration was associated with improved progression-free survival (PFS) and overall survival (OS), regardless of the treatment received. Patients with low T-cell infiltration had higher levels of immunosuppressive features in the tumor microenvironment (TME). In patients with low T-cell infiltration, treatment with canakinumab showed potential benefit, while no evidence of benefit was seen in patients with high T-cell infiltration. The study also suggested that combining canakinumab with a checkpoint inhibitor could have a positive impact on the TME. Patients with advanced NSCLC and low T-cell infiltration could potentially benefit from canakinumab in the first-line setting, but further validation is needed.<br /><br />The study was conducted as part of the CANOPY-1 trial and included 643 patients. The primary endpoints of progression-free survival and overall survival were not met in the trial. Subgroup analyses were conducted based on CD8 levels and T-cell phenotypes. The analysis showed that patients with a high T-cell infiltration status had improved OS and PFS, regardless of treatment. In patients with low T-cell infiltration, canakinumab treatment was associated with improved PFS compared to placebo, while no significant benefit was observed in patients with high T-cell infiltration.<br /><br />These findings suggest that T-cell infiltration plays a prognostic role in advanced NSCLC and can influence the response to treatment. Further studies are needed to validate these findings and explore the potential benefits of combining canakinumab with a checkpoint inhibitor in patients with low T-cell infiltration. The study was funded by Novartis Pharmaceuticals Corporation and the full results and supplementary material can be accessed online.

Asset Subtitle

Daniel Tan

Meta Tag

Speaker Daniel Tan

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

T-cell infiltration

non-small cell lung cancer

NSCLC

canakinumab

progression-free survival

overall survival

tumor microenvironment

immunosuppressive features

checkpoint inhibitor

CD8 levels